Oprava prováděcího nařízení Komise (EU) 2026/351 ze dne 18. února 2026, kterým se v souladu s nařízením Evropského parlamentu a Rady (ES) č. 1107/2009 obnovuje schválení účinné látky spinosad a mění prováděcí nařízení Komise (EU) č. 540/2011 (Úř. věst. L, 2026/351, 19.2.2026)

Corrigendum to Commission Implementing Regulation (EU) 2026/351 of 18 February 2026 renewing the approval of the active substance spinosad in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 (Official Journal of the European Union L, 2026/351, 19 February 2026)

On page 5, in Annex I, in the first paragraph of the column Specific provisions:for: For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 11 December 2025 , and in particular, Appendices I and II thereto, shall be taken into account., read: For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 21 January 2026 , and in particular, Appendices I and II thereto, shall be taken into account..

On page 7, in Annex II, in point (2), in the amendments to Part B of the Annex to Implementing Regulation (EU) No 540/2011, in the first paragraph of the column Specific provisions:for: For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 11 December 2025 , and in particular, Appendices I and II thereto, shall be taken into account., read: For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 21 January 2026 , and in particular, Appendices I and II thereto, shall be taken into account..